Overview

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

Status:
Completed
Trial end date:
2021-07-05
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
Treatments:
Tilavonemab